Quality Unit Procedures Are FDA's Most Cited Drug 483 Observation
· Updated

The observation FDA cites most often on drug inspections is 21 CFR 211.22(d), which requires the quality unit's procedures to be written and followed. It appears on 34% of drug inspections with posted citations from fiscal years 2023 to 2025. The citations that most often lead to FDA's most serious outcome are different ones, about sterile manufacturing.
A Form 483 is the list of observations an FDA investigator leaves at the end of an inspection. FDA later classifies the inspection as no action indicated (NAI), voluntary action indicated (VAI) or official action indicated (OAI). OAI means FDA recommends regulatory action, such as a warning letter.
The quality unit and investigations lead the drug list
Two sections dominate the list of drug citations, and both concern the quality unit's own system. Section 211.22(d) is a single sentence, so almost any procedure that was skipped can be cited under it. Section 211.192 requires a thorough, written investigation of any unexplained discrepancy or failed batch. Together they describe a quality unit that does not enforce its own rules. Genzyme Ireland's June 2026 warning letter cites both. FDA cited the quality unit under 211.22 because lab records left out repeated test failures, and cited 211.192 because the site cancelled deviations without finding their root cause.
| Reference | FDA's description | Inspections FY2023 to FY2025 | Share | Share FY2016 to FY2018 |
|---|---|---|---|---|
| 21 CFR 211.22(d) | Procedures not in writing, fully followed | 507 | 34% | 26% |
| 21 CFR 211.192 | Investigations of discrepancies, failures | 464 | 31% | 26% |
| 21 CFR 211.100(a) | Absence of written procedures | 346 | 23% | 16% |
| 21 CFR 211.160(b) | Scientifically sound laboratory controls | 273 | 18% | 17% |
| 21 CFR 211.68(b) | Computer control of master formula records | 217 | 15% | 10% |
| 21 CFR 211.67(a) | Cleaning, sanitizing, maintenance | 192 | 13% | 10% |
| 21 CFR 211.63 | Equipment design, size and location | 186 | 13% | 6% |
| 21 CFR 211.113(b) | Procedures for sterile drug products | 185 | 13% | 10% |
| 21 CFR 211.84(d)(2) | Reports of analysis (components) | 182 | 12% | 9% |
| 21 CFR 211.67(b) | Written procedures not established or followed | 159 | 11% | 12% |
Shares are of 1,479 drug inspections in FY2023 to FY2025 and 1,693 in FY2016 to FY2018.
Nine of the top ten references take a larger share now than in FY2016 to FY2018, partly for an arithmetic reason. Drug 483s have grown shorter, from an average of 5.4 lines in FY2011 to 4.0 in FY2025, and with fewer lines per 483 the common references take a larger share. The largest real rise was in equipment design under 211.63, which doubled from 6% to 13%. The same two sections led in both periods, so the quality unit's procedures and investigations are what an investigator is most likely to write up at any drug site.
Sterile manufacturing citations go with OAI
How often a reference is cited says little about how much trouble it signals. Of all classified drug inspections from FY2016 to FY2025, 23% ended OAI. That rate more than doubles when the 483 cites sterile controls.
The two highest rates belong to aseptic processing rules, which apply only to sterile sites. FDA already inspects those sites closely, so part of the high rate reflects the kind of site. Even so, a 483 citing environmental monitoring ended OAI 59% of the time, against 31% for one citing 211.22(d). Release testing and stability programs are not limited to sterile sites, and citations of either still ended OAI about half the time. A 483 that cites release testing or stability therefore needs the fastest and fullest response, and at a sterile site so does one about cleaning or environmental monitoring.
What to watch for on a 483
- When a 483 cites 211.22(d) or 211.192, answer for the quality unit as a whole. FDA said Genzyme's responses fixed each item but not the quality unit.
- Review cancelled or closed deviations for a recorded root cause and product impact.
- At sterile sites, treat findings on cleaning, environmental monitoring or release testing as the ones most likely to escalate.
- Before qualifying a supplier, look up which references its inspections cited.
Data and method
The data is FDA's Data Dashboard of inspection citations and final classifications for drugs, devices and biologics, from fiscal year 2009 to 20 October 2026. Each inspection counts once per reference, and its outcome is the most serious classification across its project areas. Posted citations are 74% to 89% of FDA's own yearly count of drug 483 observations, because FDA says not all inspections and citations are included. Posting lags by months, so year comparisons stop at FY2025. Any firm can be looked up in the inspection search.
Downloads: most cited references by product and fiscal year (CSV).
Frequently asked questions
What is the most common FDA 483 observation?
For drugs, 21 CFR 211.22(d), on 34% of inspections with posted citations in FY2023 to FY2025. For devices under the old quality rule, it was 21 CFR 820.100(a), CAPA procedures, on 35%.
Which regulation do device 483s cite now?
Since the QMSR took effect on 2 February 2026, device 483s mostly cite ISO 13485 clauses, and 375 of 404 device inspections with posted citations cite one. The post on ISO 13485 clauses has the ranking.
Does a longer 483 mean a worse outcome?
Not by itself. A few references, such as aseptic processing controls, go with OAI far more often than others.